Targeting the hepatocyte growth factor-cMET axis in cancer therapy - Test2 - elhamkhani - TriplyDB

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

http://www.wikidata.org/entity/Q24606259

about

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management Recent developments in receptor tyrosine kinases targeted anticancer therapy Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer Irreversible EGFR-TKIs: dreaming perfection MET inhibitors for treatment of advanced hepatocellular carcinoma: A review Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Clinical update on cancer: molecular oncology of head and neck cancer Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.Functional consequence of the MET-T1010I polymorphism in breast cancer PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.Isothiocyanatostilbenes as novel c-Met inhibitors.Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma.c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.

P2860

Q26746246-56F0B023-36F0-47DF-A6C9-86B790CCD111 Q26751331-B1BA4BF0-FAD3-43CC-881B-ADB710924E3A Q26772969-4072BEF5-E4E9-41D5-A137-848140EB44B1 Q26866186-0FC8E33A-5F02-443F-896E-D1689086C697 Q27014423-58DF7C04-526D-40C6-BED1-4F57A76E734D Q28066550-D6E96A15-7902-4FEB-86D7-D7E369948BD7 Q28071589-E53AA175-A067-4745-A375-A9BF42194227 Q28821187-9AC652BF-7061-4A3C-8D24-F3BC98FBF6A8 Q33565746-A0A626C9-0981-454A-8C97-FE512B6D352E Q33618725-EF260CA6-329B-419F-9642-9FA0C73810F4 Q33688421-B32F53DF-3B29-4E7F-93D8-05796E8DB100 Q33695197-06D37E98-02D0-4173-B809-A3EC8C25E402 Q33823715-981DBCF7-1AD5-4330-BC42-4EABA60D63BE Q33841490-0D34D863-F91C-421A-A0EC-E9A8326352B8 Q33886974-702D566C-55CB-43BE-AE1F-CA494E0819BF Q33917507-BFC5B50A-9884-43D2-BC98-6F7733EA256F Q33984904-2C91478A-BD67-4074-A363-19A46EA6C382 Q34104074-2CB141EB-EA5E-464D-9218-DC54C48D6AEC Q34104125-6DF84C7F-E7B2-4057-9CFD-05123E634D89 Q34438708-65C25065-8241-4ABB-B093-5F0B099CE24B Q35160825-7AFF83E5-B26E-499F-B8BA-B8BC4EC72DAC Q35222611-282D3538-F72E-4387-93CE-694F7D3D95D4 Q35238436-3A5EAECD-76C2-4E83-AEE4-0AA118C462E0 Q35550045-776E954F-4D9E-44CE-A8A6-5265297CD326 Q35562996-A81262AF-425B-4293-819D-160D06F3C0DC Q35605388-BD4ABC58-3B85-4659-B88A-2568C59154D4 Q35636713-A7E40E3C-E4BC-40D2-A005-96A7BE95C5E5 Q35740444-FBD56955-09FA-4880-A443-5E7F46E5240F Q35786233-CEF442BA-8C78-4B98-B82E-3111C264CF6F Q35955290-A8F5C9C5-4453-4160-8D84-367088CDCBBE Q35982925-6E3F8B44-C321-4AE6-94F1-0683DC04EBA0 Q35999644-5C4B3AC5-8009-4D3D-B811-1124A2CCCA13 Q36307708-F05F480B-9556-4357-B023-498D4FF70071 Q36544653-430688E4-CE1B-413E-AEE8-BAA5736F82A7 Q36562316-35BF2549-72EA-4D5F-8C65-A849C87A4690 Q36766188-65377194-0A31-4A0E-BF6F-AAC91525DB7C Q36953116-FF8D1892-630F-4D21-997E-5839953A8003 Q37236103-699EE5C7-4974-4ABD-A803-1E5F44903218 Q37295357-9B97F733-6EA4-4DDB-8718-8B1E61D88EB5 Q37472110-C75943B3-8959-4123-9F28-17E424E7F06D

P2860

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

http://www.wikidata.org/entity/Q24606259

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@ast

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@en

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@nl

type

label

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@ast

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@en

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@nl

prefLabel

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@ast

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@en

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@nl

P1433

Q24606259-356241EB-38C6-42F4-9F31-95B286A671F0

P1476

Q24606259-304C09F1-556D-48A7-9BF5-A05C68664CAE

P2093

Q24606259-0D6D49D4-DB73-4C41-A557-F6220067F8EB

Q24606259-427110D9-09F3-462C-88CE-17F09140F5EB

P2860

Q24606259-0341FFF8-5FFD-4477-8409-5DDE502FB938

Q24606259-07951DAC-9394-4BD2-A47F-568FD0F28130

Q24606259-07CF7850-6CDA-4BEE-B016-BB76BB753F13

Q24606259-09A189D2-D881-4713-8E7A-DEE304AF0094

Q24606259-0EC1A4FC-FFEE-47B9-956B-F67947A9590E

Q24606259-0FCC9F15-A7B1-4DCC-B9C6-40F608BA0781

Q24606259-12D45D15-4CC0-4E18-B22E-28D2A16BC45E

Q24606259-1643473E-AADD-45DE-A72A-CA24100E5677

Q24606259-16501BA2-A5D6-427F-8759-EE81D550843D

Q24606259-18FF6605-1272-4930-8BB5-A060970DB738

P304

Q24606259-D3C987DA-A6B1-400F-A94A-CC700B64ED94

P31

Q24606259-545CA8A3-088A-4F40-BBB7-78C6632F5BD2

P3181

Q24606259-79ED083C-1AF7-497C-ADE0-47D10063A1AD

P356

Q24606259-72C29D8A-4338-428F-81A8-AB34924C439E

P407

Q24606259-74DFD291-D0C1-44BD-BE2D-4E316E2DD717

P433

Q24606259-3E93F6E1-426F-4064-BD8C-D5354FC1BE53

P478

Q24606259-53308DE0-208D-4780-9083-36BD9DA9FE93

P50

Q24606259-B58DA049-F7FA-48D8-8832-CB9BF2426227

P577

Q24606259-FD204328-EDE9-4B7D-928D-6782FB8F54DC

P698

Q24606259-876FA69E-00D7-4646-A2C5-5F5644900618

P932

Q24606259-F1AE3892-C7B2-4EB9-86A7-0636F67FC579

P3181

P356

JCO.2011.40.3774

P1433

Journal of Clinical Oncology

P1476

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

@en

P2093

Ana M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

HGF/SF-met signaling in the control of branching morphogenesis and invasion

Invasive growth: a MET-driven genetic programme for cancer and stem cells

P304

3287-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2431376

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2011.40.3774

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

George R Blumenschein

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22869872

http://www.w3.org/2001/XMLSchema#string

P932

3434988

http://www.w3.org/2001/XMLSchema#string